AI assistant
Rua Bioscience Limited — Capital/Financing Update 2025
Dec 15, 2025
66262_rns_2025-12-16_4f7f9890-4825-4c4a-bf2e-4477673a665e.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
PRO RATA RIGHTS ISSUE UPDATE
==> picture [132 x 77] intentionally omitted <==
FOR PUBLIC RELEASE
NZX Limited Wellington
16 December 2025
Successful rights offer is oversubscribed
Rua Bioscience Limited announces the successful completion of its 1 for 3 renounceable rights offer at an issue price of $0.025 per new share. The rights offer sought to raise $2.034 million.
The rights issue which closed on Friday 12 December 2025, was oversubscribed with applications received of $2.316 mill. This is $282k or 14% more than the amount requested under the offer.
The Board has resolved to accept oversubscriptions in excess of the rights offer through a placement to an existing eligible investor of approximately $280,000, at the same issue price of $0.025 per share.
The allotment and issue of new shares will occur on Thursday 18 December 2025. Holding Statements will be dispatched to shareholders on Monday 22 December 2025
Rua Bioscience Chair, Anna Stove commented, “The strong level of shareholder support is a clear endorsement of our strategy and the progress being made by the Rua team. On behalf of the Board and the Rua team, I would like to thank our shareholders for their continued support.”
Rua Bioscience remains committed to its export-led growth strategy, leveraging its international partnerships and it’s expertise in unique genetic development to deliver high-value medicinal cannabis products to patients.
ENDS
The person who authorised this announcement:
Paul Naske Chief Executive Officer [email protected] +64 21 445154
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com